IAG Capital Partners
VC Fund
Charleston, United States
IAG Capital Partners is an investment firm that sole source of financing and investment rounds with other debt and equity investors.
- Total investments:
- 76
- Last investment:
- Lead investor:
- 39%
Last updated:
For AI agents: llms.txt
Industries IAG Capital Partners invests in
Stages IAG Capital Partners invests in
Countries IAG Capital Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
2 more contacts available
Round size
- Seed
- $1.1M–$26M
- Series A
- $5M–$35M
- Series B
- $6M–$100M
Investment Focus
Industry
- Artificial Intelligence 14 (18%)
- Software 13 (17%)
- Health Care 11 (14%)
- Medical Device 11 (14%)
- Biotechnology 10 (13%)
Stage
- Series A 16 (21%)
- Series B 16 (21%)
- Seed 15 (20%)
- Series C 6 (8%)
- Funding Round 5 (7%)
Country
- United States 42 (55%)
- Canada 2 (3%)
- Ireland 2 (3%)
- United Kingdom 2 (3%)
- Spain 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Alex Kash
Associate
|
Associate | Total investments: 3 | Find email | |
|
Alonso Galván
ff; Founding Principal
|
ff; Founding Principal | Total investments: 3 | Find email | |
Ehsan Jabbarzadeh
Venture Partner
|
Venture Partner | Total investments: 5 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Neurosoft Bioelectronics
|
Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the nervous system. Neural implants are medical devices made of electrodes that can record or stimulate the brain, spinal cord, or peripheral nerves to monitor or treat patients suffering from neurological disorders. However, current clinicaldevices are too stiff compared to the soft tissues of the body, which limits benefits for patients. At Neurosoft Bioelectronics, we have developed a new generation of soft and conformable implantable electrodes that seamlessly interface with the nervous tissues and can improve clinical outcomes for patients. | $7.5M / Seed / May 20, 2026 | |
Tamber
|
Tamber is an AI-powered creative suite for musicians. It acts as a "bionic arm" that enhances production workflows using sonic intelligence for real-time sound control via text, voice, or gestures. | $5M / Seed / Apr 23, 2026 | |
Xscape Photonics
|
Xscape Photonics provides photonic chips for high-speed connections in high-performance computing systems and data centers. The company uses photonics to realize scalable, high-bandwidth, energy-sustainable, and cost-effective solutions that enable the next generation of AI, ML, and simulation hardware. | $37M / Series A / Mar 11, 2026 | |
Cognito Therapeutics
|
Cognito Therapeutics develops neurotechnology therapies designed to treat neurodegenerative diseases by stimulating specific brain activity patterns. The company focuses on noninvasive therapeutic systems that use synchronized visual and auditory stimulation to influence neural activity associated with cognitive function and brain health. Itstechnology platform, Spectris, is designed to evoke gamma-frequency brain waves, which play a role in learning, memory, and communication between neurons. The platform delivers controlled light and sound signals through a wearable device to trigger gamma oscillations in the brain, a pattern of neural activity that is disrupted in conditions such as Alzheimer’s disease. By restoring this activity, the therapy aims to support processes related to synaptic function, myelin integrity, and neural connectivity.Cognito Therapeutics conducts clinical research and trials to evaluate how its neuromodulation technology affects cognitive performance, brain structure, and functional abilities in patients with neurodegenerative disorders. The company studies the biological effects of sensory stimulation on brain pathways, immune responses, and neural signaling networks associated with disease progression. Through its research programs and device development, Cognito Therapeutics produces medical technologies intended for clinical treatment and investigation of neurological conditions that affect memory, cognition, and daily functioning. | $105M / Series C / Mar 05, 2026 | |
Pharaoh Neuro
|
Pharaoh Neuro develops a neurapheresis cerebrospinal fluid management system for neurological patients. | $20M / Series A / Feb 18, 2026 | |
Trener Robotics
|
T-robotics uses end-to-end neural networks and constraint-based programming to train AI skills for robots. These skills are directly deployable on all major commercially available robot brands. These skills allow these robots to fail less, perform complex tasks, and program easily. | $32M / Series A / Feb 10, 2026 | |
Resemble AI
|
Resemble AI creates custom voices using proprietary deep-learning models that can produce realistic speech synthesis. It allows users to transform their voice into the target voice with real-time speech-to-speech. Granular control over every inflection and intonation. | $13M / Dec 07, 2025 | |
Archetype AI
|
Archetype AI is a group of designers and technologists they are pioneering revolutionary artificial intelligence and interaction technologies for the real world. | $35M / Series A / Nov 20, 2025 | |
RAAAM Memory Technologies Ltd.
|
RAAAM provides a unique on-chip memory technology that offers the highest-density embedded memory solution in any standard CMOS process.RAAAM develops a high-density memory technology that allows for up to 50% higher on-chip memory density with no cost, complexity, or performance-penalty. | $17.5M / Series A / Nov 04, 2025 | |
proteanTecs
|
ProteanTecs provides a platform that enables continuous monitoring of electronic systems by embedding sensor-like Agents into chips, which generate data throughout the entire lifecycle. It offers software tools and analytics that transform this telemetry into actionable insights about performance, reliability, and production quality. The platformapplies machine learning to on-chip data, enabling the detection of anomalies and early warnings before issues manifest in the field. The solution spans stages from chip design through production to in-field operation, ensuring traceability and diagnosing faults across the electronics value chain. | $51M / Series D / Sep 09, 2025 | |
| See all 76 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does IAG Capital Partners invest in?
IAG Capital Partners invests primarily in Artificial Intelligence, Software and Health Care startups, most often at Series A and Series B stage. Most of the 76 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is IAG Capital Partners's check size?
IAG Capital Partners typically joins rounds of $1.1M–$26M at Seed, $5M–$35M at Series A and $6M–$100M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds IAG Capital Partners participates in.
How do I contact IAG Capital Partners?
Public channels for IAG Capital Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at IAG Capital Partners?
The team at IAG Capital Partners includes Alex Kash (Associate), Alonso Galván (ff; Founding Principal) and Ehsan Jabbarzadeh (Venture Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
